Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company
featuring personalized knee and hip replacement products, recently
launched a patient education and awareness campaign in selected
U.S. markets to strengthen the importance of patient choice by
highlighting the differences between traditional “off-the-shelf”
products and truly personalized knee systems that offer clinically
proven benefits to patients.
The campaign is currently airing in the Boston, MA and
Minneapolis-St. Paul, MN metro areas in an effort to educate future
patients about their options when it comes to total knee
replacement surgery. Independent surveys and Conformis market
research show that most of the growing total knee replacement
patient population is unaware of stark differences in knee
replacement systems, and simply receives the brand of knee
replacement system used most frequently by their surgeon.
Conformis makes fully personalized or patient specific knee
systems for each patient using advanced 3D imaging technology,
which is designed to produce an implant that matches each patient’s
unique anatomy, and is designed to offer multiple benefits to
patients and medical facilities that have been demonstrated in
peer-reviewed clinical studies:
- Patients reporting significant higher fulfillment of their
expectations regarding post-op function and knee strength1.
- Significant bone sparing as compared to traditional total knee
arthroplasty2.
- Lower total direct costs for hospital admissions, with
variables such as operative time and length of stay favoring fully
personalized implants3.
“The U.S. healthcare system is based on choice, yet many
patients don’t know they have a choice when it comes to knee
replacement surgery, an operation performed several hundred
thousand times each year throughout the nation,” said James Paiva,
Vice President of Marketing for Conformis. “The highest probability
of success is the combination of a great surgeon with a great
implant that matches the patient’s anatomical structure, along with
great post-operative physical therapy. Through this awareness
campaign, our goal is to highlight how a patient’s choice of
implant used during their knee replacement surgery can have a big
impact on the level of mobility and quality of life.”
More than 50 peer-reviewed studies and articles published in
medical journals indicate that fully personalized implants can
reduce total costs to the healthcare system because patients
recover more quickly and are less likely to require follow-up
corrective (revision) surgeries. In addition, according to the
study published in The Journal of Bone & Joint Surgery
Reviews (JBJS Reviews)4, patients who had undergone bilateral
total knee arthroplasty (TKA) preferred their Conformis fully
personalized knee compared to their bilateral off-the-shelf knee at
a rate of more than 10 to 1.
The Conformis patient awareness campaign, whose primary
television spot is seen here, is currently running in the Greater
Boston-Seacoast New Hampshire and Metro Minneapolis-St. Paul
markets through March. For more information about Conformis and the
company’s fully personalized and made-to-measure knee replacement
systems, please visit www.conformis.com.
1 Zeh, Alexander; Gehler, Valentina; Gutteck, Natalia; Beckmann,
Johannes; Brill, Richard; Wohlrab, David. Superior
Clinical Results and Higher Satisfaction after Customized Compared
with Conventional TKA. Acta
Orthopaedica Belgica: December 2021 – Volume 87 – Issue
4 https://doi.org/10.52628/87.4.10 2
Kurtz, William, John Slamin, and Scott Doody. Bone
Preservation in a Novel Patient Specific Total Knee
Replacement. Reconstructive Review 6.1 (2016):
23-29.https://www.reconstructivereview.org/ojs/index.php/rr/article/view/133/164http://dx.doi.org/10.15438/rr.6.1.133
3Custom-designed total knee arthroplasty is cost-effective in
comparison to a standard implant, Navin Fernando MD, Ann Chancellor
CCRC, Paul Manner MD, University of Washington, Seattle, WA, 2021
Proceedings of Orthopaedic Research Society, Paper 0980
4 Schroeder, Lennart ; Dunaway, Andrew DO2; Dunaway, Daniel MD3
A Comparison of Clinical Outcomes and Implant Preference of
Patients with Bilateral TKA. JBJS Reviews: February 2022 -
Volume 10 - Issue 2 - e20.00182 doi: 10.2106/JBJS.RVW.20.00182
About Conformis, Inc. Conformis is a medical
technology company focused on advancing orthopedic patient care and
creating a world without joint pain. Its product portfolio is
designed to maximize surgeon and patient choice by offering fully
personalized solutions through its Image-to-Implant® Platinum
Services℠ Program as well as data-informed, standardized solutions
that combine many benefits of personalization with the convenience
and flexibility of an off-the-shelf system. Conformis’ sterile,
just-in-time, Surgery-in-a-Box™ delivery system is available with
all of its implants and personalized, single-use instruments.
Conformis owns or exclusively in-licenses issued patents and
pending patent applications that cover personalized implants and
patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future
press releases via e-mail alerts, sign up at
ir.conformis.com.Cautionary Statement Regarding
Forward-Looking StatementsStatements in this press release
about our future expectations, plans and prospects, including
statements about the anticipated timing of our product launches,
and our financial position and results, total revenue, product
revenue, gross margin, operations and growth, as well as other
statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "predict," "project," "should,"
"target," "will," or "would" and similar expressions, constitute
forward-looking statements within the meaning of the safe harbor
provisions of The Private Securities Litigation Reform Act of 1995.
We may not actually achieve the forecasts disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual financial results could
differ materially from the projections disclosed in the
forward-looking statements we make as a result of a variety of
risks and uncertainties, including risks related to our estimates
and expectations regarding our revenue, gross margin, expenses,
revenue growth and other results of operations, and the other risks
and uncertainties described in the "Risk Factors" sections of our
public filings with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent our views as of the date hereof. We anticipate
that subsequent events and developments may cause our views to
change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date hereof.
INVESTOR CONTACT
ir@conformis.com781.374.5598
Source: Conformis, Inc.
Conformis (NASDAQ:CFMS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Conformis (NASDAQ:CFMS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024